FDA To Act On COX-2 Committee Input Within "Next Few Weeks"
This article was originally published in The Pink Sheet Daily
Executive Summary
In remarks to the Arthritis Drugs/Drug Safety & Risk Management advisory committee meeting, CDER Acting Director Galson says the agency will take "rapid" action on the panel's recommendations.
You may also be interested in...
Celebrex Has No Apparent MI Signal At 200 Mg Or Less, FDAer Graham Says
The drug safety officer's meta-analysis suggests that Celebrex and Bextra can both be safely marketed at low doses, but Vioxx poses a risk at both the 25 mg and 50 mg doses. At committee meeting, Graham discusses results of two unpublished studies, which he says he was initially told by FDA not to present.
COX-2 Inhibitors Contraindicated For Heart Disease Patients In Europe
European Medicines Agency says COX-2 inhibitors should not be used in individuals with ischemic heart disease or stroke and recommends caution when prescribing the drugs for patients with risk factors for heart disease. Agency also adds a hypertension contraindication for Merck’s Arcoxia.
COX-2 Inhibitors Contraindicated For Heart Disease Patients In Europe
European Medicines Agency says COX-2 inhibitors should not be used in individuals with ischemic heart disease or stroke and recommends caution when prescribing the drugs for patients with risk factors for heart disease. Agency also adds a hypertension contraindication for Merck’s Arcoxia.